Bristol Myers Squibb (BMY)
NYSEHealth CareDrug Manufacturers - GeneralSnapshot 2026-07-08
$57.98+2.25%
Close 2026-07-07 · 1-day change
Reading BMY? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track BMY free→NYSEHealth CareDrug Manufacturers - GeneralSnapshot 2026-07-08
Reading BMY? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track BMY free→A long-form read on the 1–3 year hold thesis. Slower and deeper than the daily snapshot — it refreshes only when the evidence moves.
This investment represents a durable compounder with a stable management team. The current thesis state is intact, supported by recent strong financial performance despite mixed guidance on future expectations.
The market currently prices BMY as cheap compared to its peers, with a low expectations gap. This suggests that investors are not overly optimistic about future growth, allowing for potential upside if performance improves.
Fundamentals are likely to remain stable, given the low risk profile and strong recent financial performance. However, there is a mixed outlook on management's ability to reaffirm guidance, which could impact future results.
The thesis hinges on management's ability to maintain or improve financial guidance and the performance of sector bellwethers like LLY, JNJ, and ABBV. Any changes in guidance or performance from these companies could significantly affect BMY's trajectory.
Overall, BMY's position appears solid for the next 1 to 3 years, but it is sensitive to sector dynamics and management execution. Not investment advice.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. The latest earnings beat supports a positive outlook. The company is launching new products and aligning with financial guidance. There are no current threats to this view.
as of 2026-07-08
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Why it matters: Eliquis brings in a lot of revenue. Changes could show shifts in market or competition.
Confirms:Eliquis revenue growth reported above 10% year over year in Q2 2026.
Disproves:Eliquis revenue growth reported below 5% year over year in Q2 2026.
Why it matters: Reaffirming guidance shows confidence in growth. This happens even with recent income decline.
Confirms:Management confirms revenue for 2026 will be between $46.0 billion and $47.5 billion.
Disproves:Management cuts revenue guidance to less than $46.0 billion.
Why it matters: Maintaining gross margin is key for profitability. A drop could signal deeper issues.
Confirms:Gross margin remains stable or improves from 70.2% in Q1 2026.
Disproves:Gross margin declines below 70.2% in Q2 2026.
Why it matters: Keeping gross margin guidance is key for making money. A drop could mean pricing or cost problems.
Confirms:Gross margin remains stable or improves compared to Q1 levels.
Disproves:Gross margin declines from the 70.2% reported in Q1.
Why it matters: Good results could lead to approval. This would expand treatment options for multiple myeloma and increase future revenue.
Confirms:Positive results come from the Phase 3 trial for Iberdomide.
Disproves:Trial results show no big change in patient outcomes.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.